title: [Attention to the non-responders to anti-VEGF treatment of wet age-related macular disease].
abstract: Intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) drugs has become the standard treatment for exudative age-related macular degeneration (AMD). However, there are some patients who do not have a sufficient response to the treatment, and some patients fail to respond to those drugs. The mechanisms of non-response to the treatment in these cases are poorly understood. These may be associated with wAMD types, vitreomacular abnormity, genetic factors, and tachyphylaxis, etc. Ophthalmologists should pay attention to those non-responders and give them the correct treatment, avoid the anti-VEGF drugs abuse and explore the best personalized treatment for those patients.
authors.affiliation: Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China. Email: zhangmeixia@medmail.com.cn.
authors.forename: Meixia
authors.initials: M
authors.lastname: Zhang
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001288:Attention; D006801:Humans; D017211:Treatment Failure; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A